Clinical Trial Update: A Trial of CS-747 (Prasugrel) Compared With Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention (PCI) [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing prasugrel (CS-747) with clopidogrel in patients undergoing percutaneous coronary intervention (PCI) has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Diseases
• Heart Diseases

Drugs mentioned

• CLOPIDOGREL (CLOPIDOGREL)
• PRASUGREL (prasugrel)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Cardiovascular Diseases, Heart Diseases | Phase 2 | Status: COMPLETED | Results posted: 2010-05-21